BioTelemetry, Inc. (NASDAQ:BEAT) insider Fred Broadway sold 54,158 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $34.17, for a total value of $1,850,578.86. Following the transaction, the insider now directly owns 64,880 shares in the company, valued at $2,216,949.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BioTelemetry, Inc. (NASDAQ BEAT) traded down $0.05 during trading hours on Wednesday, reaching $33.90. The company had a trading volume of 391,361 shares, compared to its average volume of 449,594. The firm has a market capitalization of $1,100.00, a price-to-earnings ratio of -63.96, a P/E/G ratio of 1.77 and a beta of 0.75. BioTelemetry, Inc. has a 1 year low of $23.30 and a 1 year high of $39.20. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80.
BioTelemetry (NASDAQ:BEAT) last released its earnings results on Thursday, February 22nd. The medical research company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. The firm had revenue of $91.70 million for the quarter, compared to analyst estimates of $88.33 million. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. BioTelemetry’s revenue was up 69.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.23 earnings per share. equities analysts anticipate that BioTelemetry, Inc. will post 1.28 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC acquired a new position in BioTelemetry during the fourth quarter worth about $12,910,000. MetLife Investment Advisors LLC acquired a new position in BioTelemetry during the fourth quarter worth about $397,000. Lyon Street Capital LLC grew its holdings in BioTelemetry by 2,368.9% during the fourth quarter. Lyon Street Capital LLC now owns 379,029 shares of the medical research company’s stock worth $11,333,000 after acquiring an additional 363,677 shares during the period. Macquarie Group Ltd. grew its holdings in BioTelemetry by 8,866.8% during the fourth quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock worth $22,612,000 after acquiring an additional 747,829 shares during the period. Finally, Vident Investment Advisory LLC acquired a new position in BioTelemetry during the fourth quarter worth about $612,000. 87.49% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/fred-broadway-sells-54158-shares-of-biotelemetry-inc-beat-stock.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.